Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

In a phase I trial for patients with advanced ovarian cancer, irinotecan and carboplatin were administered at 6 different dose levels to determine maximum tolerated dose. The dose-limiting toxicity was hematologic (neutropenia and thrombocytopenia). The recommended dose for the Phase II study was irinotecan 60 mg/m2 on Days 1, 8, and 15 and carboplatin 5 mg/mL (AUC) on day 1, repeated every 4 weeks. Of note, of the ten patients with measurable disease, criteria for treatment response were achieved in 5. This level of response bodes well for this combination.

Second-Line Irinotecan and Carboplatin for Advanced Ovarian Cancer: Phase 1